fbpx A new era for noninvasive cancer diagnosis | Page 8 | Science in the net
  1. Noninvasive cancer diagnosis
  2. Revisions
  3. A new era for noninvasive cancer diagnosis

A new era for noninvasive cancer diagnosis

Pubblicato il 11/02/2013Read time: 2 mins

Tumors release microvescicles containing protein and RNA fragments, called exosomes, into cerebral spinal fluid, blood, and urine. Exosome Diagnostics, a company based in New York, has developed a diagnostic test able to separate exosomes from bio-fluids and to extract their relevant genomic information. A team of researchers from the Massachusetts General Hospital reported that exosomes preserve the genetic information of their parental cells. By analyzing the genetic material contained in the exosomes, researchers aim to get accurate information about the nature, molecular composition and progression of the tumor.

Providing an early and accurate cancer diagnosis represents one of the major challenges in the battle against tumors. Nowadays a tissue biopsy is generally required in order for the doctors to formulate a correct diagnosis of the type of cancer and its progression status. However, for some tumor types, biopsies are invasive procedures with potential damaging side effects that, in extreme cases, could be life threatening.

A promising alternative to biopsies that hold the potential to revolutionize the cancer diagnosis field comes from studies on the communication between cancer cells and their microenvironment.

A multicenter clinical study using the Exosome diagnostic kit is now underway to validate this new strategy in glioblastoma (the most common form of brain cancer). Clinicians will periodically draw bio-fluids to monitor the state of the disease and will determine whether a patient is responding to therapy, something unthinkable until recently due to the extremely invasive nature of these kinds of biopsies.

Exosome diagnostic kits could potentially detect and monitor the progression of a wide variety of cancers, like prostate cancer. The most common noninvasive test for prostate cancer measures the blood level of PSA, a protein that is produced by the prostate gland. The higher a man’s PSA level, the more likely it is that he has prostate cancer. Nevertheless PSA test alone is not sufficient to accurately and undoubtedly detect prostate cancer. Exosome diagnostic kits specific for prostate cancer represent a substantial alternative to PSA test or they could be used in conjunction with current methods of diagnosis.Although more tests are required, exosomes hold promise to become an invaluable diagnostic tool to be exploited.

http://www.scientificamerican.com/article.cfm?id=rna-fragments-may-yield-rapid

Autori: 
di Francesca Zammarchi
Tumors diagnostic test
  • 4891 reads

prossimo articolo

Discovered a New Carbon-Carbon Chemical Bond

di Chiara D'Errico
Pubblicato il 16/10/2024

A group of researchers from Hokkaido University has provided the first experimental evidence of the existence of a new type of chemical bond: the single-electron covalent bond, theorized by Linus Pauling in 1931 but never verified until now. Using derivatives of hexaarylethane (HPE), the scientists were able to stabilize this unusual bond between two carbon atoms and study it with spectroscopic techniques and X-ray diffraction. This discovery opens new perspectives in understanding bond chemistry and could lead to the development of new materials with innovative applications.

In the cover image: study of the sigma bond with X-ray diffraction. Credits: Yusuke Ishigaki

Chemistry

After nearly a year of review, on September 25, a study was published in Nature that has sparked a lot of discussion, especially among chemists. A group of researchers from Hokkaido University synthesized a molecule that experimentally demonstrated the existence of a new type of chemical bond, something that does not happen very often.